| GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track | Mandy Jackson | 06/12/20 | National |
| Tango Adds $60M in CRISPR Hunt for Synthetically Lethal Cancer Drugs | Frank Vinluan | 04/09/20 | Boston |
| Cyteir Adds $40M for Clinical Test of “Synthetically Lethal” Cancer Drug | Frank Vinluan | 10/15/19 | Boston |
| Bio Roundup: PARP Progress, A New Commish, IPO-Palooza & More | Ben Fidler | 10/04/19 | National |
| GSK’s Cancer Comeback Continues With Data for Multiple Myeloma Drug | Frank Vinluan | 08/23/19 | National |
| Bio Roundup: Opioid Exposé, Gilead’s Gambit, Life Science IPOs & More | Frank Vinluan | 07/19/19 | National |
| No Details, But AstraZeneca Touts PARP Drug Win in Pancreatic Cancer | Ben Fidler | 02/26/19 | New York |
| AbbVie Joins Myeloma Race with $90M Deal for Rights to Teneobio Drug | Frank Vinluan | 02/11/19 | San Francisco |
| Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More | Ben Fidler | 02/08/19 | National |
| Bio-JPM Roundup: Lilly Buys Loxo, Sage’s Stock Soars, ALS Cash & More | Frank Vinluan | 01/07/19 | National |
| Eli Lilly Makes an $8B Cancer Genetics Bet with Loxo Acquisition | Frank Vinluan | 01/07/19 | Indiana |
| Ribon Raises $65M to Pursue PARP-Blocking Pills for Cancer | Corie Lok | 01/04/19 | Boston |
| Bio Roundup: ASH Wrap, CRISPR Baby Fallout, Moderna’s Record IPO | Ben Fidler | 12/07/18 | National |
| GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca | Ben Fidler | 12/03/18 | Boston |
| Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive’s End | Ben Fidler | 10/19/18 | National |
| AstraZeneca’s PARP Drug Is First to Help New Ovarian Cancer Patients | Ben Fidler | 06/27/18 | National |
| Cancer Wrap: Blueprint, Checkmate, More AACR News & Phase 3 Blues | Alex Lash | 04/18/18 | National |
| Cyteir Bags $29M to Tap “Self Destruct” in Cancers, Immune Diseases | Frank Vinluan | 03/08/18 | Boston |
| SpringWorks Spins Out of Pfizer With $103M to Give Shelved Drugs New Life | Ben Fidler | 09/25/17 | New York |
| Last Chance to Save on Boston’s Life Science Disruptors | Jamie Gulden | 09/20/17 | Boston |
| Bio Roundup: RNAi Drama, Immunotherapy Data, Lasker Winners & More | Ben Fidler | 09/08/17 | National |
| Catch Dragonfly, IFM, Tesaro at “Disruptors” on Sept. 28 | Ben Fidler | 09/05/17 | Boston |
| Power to the Patient: Meet Xconomy’s Patient Partnership Award Finalists | Corie Lok | 08/28/17 | Boston |
| Startup Builders, IPO Closers & More: Meet Xconomy’s CEO Award Finalists | Ben Fidler | 08/10/17 | Boston |
| Dragonfly, Tyler Jacks Sign On for Boston’s Life Science Disruptors on Sept. 28 | Jamie Gulden | 08/09/17 | Boston |
| Check Out Tesaro & More at “Disruptors” on Sept. 28; Super Saver Rate Ends Today | Jamie Gulden | 08/03/17 | Boston |
| Bio Roundup: GOP Drama, Immunotherapy Setbacks, Pharma Revamps | Ben Fidler | 07/28/17 | National |
| Tesaro Cashes In Again on PARP Blocker With $100M Takeda Deal | Frank Vinluan | 07/27/17 | Boston |
| Join Tesaro and Others at Boston’s Life Science Disruptors Sept. 28 | Jamie Gulden | 07/13/17 | Boston |
| New Ovarian Cancer Data Suggests Larger Role For Top Clovis Drug | Alex Lash | 06/19/17 | Boulder/Denver |
